Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Blood|February 23, 2013
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDCatherine C Smith, Elisabeth A Lasater, Xiaotian Zhu, et al.
Human Molecular Genetics|April 30, 2008
Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathwayElisabeth A Lasater, Waylan K Bessler, Laura E Mead, et al.
Cancer Discovery|December 24, 2013
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addictionJennifer Asmussen, Elisabeth A Lasater, Cheryl Tajon, et al.
Elife|December 23, 2014
Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapyAlexander A Warkentin, Michael S Lopez, Elisabeth A Lasater, et al.
The Journal of Clinical Investigation|February 18, 2010
Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humansElisabeth A Lasater, Fang Li, Waylan K Bessler, et al.
Haematologica|May 17, 2020
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia modelsRaghuveer Singh Mali, Qi Zhang, Rosa Anna DeFilippis, et al.
Nature Chemical Biology|March 4, 2014
Dual kinase-bromodomain inhibitors for rationally designed polypharmacologyPietro Ciceri, Susanne Müller, Alison O'Mahony, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2014
Crenolanib is a selective type I pan-FLT3 inhibitorCatherine Choy Smith, Elisabeth A Lasater, Kimberly C Lin, et al.
Blood|December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomasStephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
JCI Insight|May 10, 2016
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A Minson, Catherine C Smith, Deborah DeRyckere, et al.
Pageof 2